ABSTRACT
In the United States, Lyme disease is caused by Borrelia burgdorferi sensu stricto, which is transmitted by the bite of infected Ixodes scapularis and Ixodes pacificus ticks. 1 A recently described bacterium, Borrelia mayonii, has also been shown to cause Lyme disease. 2 Each year, at least 3.4 million Lyme disease tests are performed by commercial laboratories and an estimated 300,000 persons are diagnosed with Lyme disease. 2, 3 Most cases occur in the Northeast, mid-Atlantic states, and upper Midwest, with a smaller number of cases in Pacific Coast states. In Vermont, the incidence of Lyme disease is high (71 cases per 100,000 persons per year), and the number of reported cases has steadily increased since 2005. 4 Patients with erythema migrans who live in or have traveled to areas endemic for Lyme disease can be diagnosed without laboratory testing. For all other patients, the Centers for Disease Control and Prevention (CDC) currently recommends a two-tiered serologic test that detects antibodies against B burgdorferi ❚Figure 1❚. 5 The first step uses an enzyme immunoassay (EIA) or immunofluorescent assay (IFA) to quantify total potential antibodies against B burgdorferi. If the first-step EIA or IFA is negative, no further testing of the specimen is necessary. If positive or equivocal, the second step, Western immunoblotting (WB), should be performed to assess for the presence of antibodies specific to B burgdorferi proteins. For patients who have had signs or symptoms for 30 days or less, both immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies should be assessed. For those who have been ill for more than 30 days, only WB IgG antibodies should be assessed, since this is typically sufficient to detect infection and avoids potential false-positive results from cross-reactive IgM antibodies. Results of two-tiered serology are considered positive only if the EIA is positive or equivocal and the WB is also positive (Figure 1 ). 5, 6 Because serology detects the body's immune response to infection, it has low sensitivity during the first few weeks of infection while antibodies are still developing. 7, 8 After this time, sensitivity of two-tiered testing increases to 70% to 80% for early disseminated disease and nearly 100% for late disease. Because antibodies can persist for years after infection, serology should not be used as a test of cure. 9 In addition to the recommended serologic tests, several other tests are available. Culture and polymerase chain reaction (PCR) assays of cerebrospinal fluid (CSF), skin biopsy specimens, or blood can occasionally be useful but are limited by low clinical sensitivity and are more commonly used in the research setting. Although PCR of synovial fluid is reasonably sensitive in patients who have not been treated, serologic testing remains the preferred diagnostic method for confirming Lyme disease in patients with arthritis. 10 Some commercial laboratories claim to specialize in testing for tickborne diseases and offer their own laboratory-developed tests for Lyme disease. Tests offered include urine antigen assays, lymphocyte transformation tests, quantitative CD57 assays, and measurements of antibodies in synovial fluid. 14 Although national data indicate there is some confusion with testing, detailed and systematic information on laboratory testing knowledge and practices by clinicians is limited. This information would help tailor educational interventions and evaluate potential improvements to the laboratory ordering and reporting system. The objective of this study was to describe clinicians' knowledge and practices regarding diagnostic testing for Lyme disease in Vermont.
Materials and Methods
This study was conducted at UVMMC, Vermont's only academic medical center. Located in Burlington, the state's largest city, it functions as a regional referral center for approximately 1 million people and a community hospital for 160,000 individuals. As a regional reference laboratory, UVMMC performs approximately 2.7 million tests annually. For Lyme disease testing, the UVMMC laboratory performs the recommended two-tiered serologic test in house. Two outlying hospitals perform their own Lyme EIA tests and, if positive or equivocal, send samples to UVMMC for follow-up WB testing. Otherwise, the WB as a standalone test is not offered by UVMMC, according to current guidelines. To order Lyme disease testing, clinicians ❚Figure 1❚ Two-tiered serologic testing algorithm for Lyme disease.
order the "Lyme antibody" test. If the EIA is negative, the result is reported as "negative." If the EIA is positive or equivocal, that result is reported as "Lyme antibody screen positive or equivocal. Western blot confirmation to follow." For WB testing, the result is reported as positive or negative for IgM and IgG, as well as the specific bands identified. Comments are included in the report to aid in interpretation (see Discussion section for complete comments).
UVMMC also offers CSF antibody testing; PCR on serum, CSF, and synovial fluid; and a serum tick-borne disease antibody panel as send-out tests through the Mayo Medical Laboratories. The serum tickborne disease antibody panel includes the two-tiered serologic testing for Lyme disease.
We developed an online survey consisting of 13 questions regarding clinician characteristics and knowledge, attitudes, and practices related to diagnostic testing for Lyme disease (Supplementary Figure 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). A link to this anonymous survey was sent to 1,142 clinicians who had ordered any laboratory test from UVMMC within the past year. The survey collected information on respondent demographics, basic Lyme disease testing knowledge, alternative testing requests, and confusion with test interpretation. We also asked respondents to rate their satisfaction with the UVMMC laboratory's Lyme disease test ordering system and the Lyme disease test result reporting system. A freetext option was available for some questions to allow respondents to elaborate on their responses.
The UVMMC Laboratory Customer Service team collects basic information on phone calls received as part of standard practice. We collected additional data regarding phone calls received about Lyme disease testing prospectively during a 6-month period from May to October 2015. Customer service representatives filled out a standard data collection form each time they received a phone call regarding Lyme disease testing (Supplementary Figure 2) .
Responses were summarized using descriptive statistics. Inferential statistical calculations were performed with parametric methods using the SAS program, version 9.3 (SAS Institute, Cary, NC). Fisher exact test was used to compare the proportion of survey questions answered correctly among clinicians using the R program, version 3.3.1 (R Core Team, 2016). 15 We compared the performance of those in primary care specialties, who are likely to be the first health care contacts of potential patients with Lyme disease, with those in other specialties; we excluded infectious disease specialists from this comparison since they likely have more detailed knowledge of testing protocols, and numbers were too few to perform separate statistical analyses.
The study was reviewed and approved by the University of Vermont Institutional Review Board.
Results

Clinician Survey
Of 1,142 survey links sent, 192 surveys were started and 147 were completed, yielding a 12.9% response rate. Of the 147 completed surveys, three were excluded because respondents were not physicians, nurse practitioners, physician assistants, or naturopathic providers. Thus, 144 total responses were included.
Characteristics of survey respondents are listed in ❚Table 1❚. All respondents practiced within Vermont, primarily in the greater Burlington area.
Of three knowledge questions, the mean number of correct responses for all respondents was 2.1 with a standard deviation of 0.7 ❚Table 2❚. Most clinicians obtained a score of 2 (73, 50.7%) or 3 (44, 30.6%). Using the Fisher exact test, we found no significant difference between the performance of clinicians working in primary care from those working in other noninfectious disease specialties (P = .84). Infectious disease specialists did have an overall higher score (2.8 correct answers for infectious disease vs 2.1 for primary care and 2.0 for others); however, statistical analyses were not performed given the low number of infectious disease specialists. Many respondents reported that patients had asked them for nonstandard serology (38.2%) or unvalidated tests from Lyme disease "specialty" laboratories (21.5%) (❚Table 3❚, questions 4 and 5). This was particularly true among primary care practitioners and infectious disease specialists. In addition to the nonstandard tests listed in Table 3 , other free-text responses for tests requested included urine antigen testing and direct testing of ticks.
When asked specifically about WB interpretation, many respondents (44.4%) indicated that a positive IgM WB result in a patient with longstanding symptoms lasting more than 30 days had created confusion for either themselves or their patients (❚Table 4❚, question 6). Similarly, many (46.5%) responded that a laboratory report that listed individually positive WB bands in the context of an overall negative test had also caused confusion for either themselves or their patients (Table 4 , question 7). Again, primary care practitioners and infectious disease specialists reported the majority of these problems.
Among the 142 respondents who answered a question about satisfaction with the UVMMC Lyme disease test ordering system, most indicated they were somewhat or very satisfied (85, 59.9%) or neutral (49, 34.5%). Most also indicated that they were somewhat or very satisfied (89, 62.7%) or neutral (47, 33.1%) with regard to the Lyme disease test reporting system. Some free-text comments indicated lack of knowledge or confusion about appropriate Lyme disease testing. For example, some clinicians responded that they would like to be able to order WB outside of the two-tiered testing algorithm, which is not recommended. One clinician also indicated that patients asking for nonstandard tests either have seen or would eventually see clinicians who have deemed themselves to be Lyme specialists.
Lyme Disease Testing
A total of 20,295 serum EIA tests were performed during the 2.5-year study period. The median age of patients tested was 49 years for female patients and 52 years for male patients; most EIA test samples were from female patients (55.3%). The largest number of EIA tests was ordered for women aged 50 to 59 years (Supplementary Figure 3) . A total of 1,488 serum EIA tests (7.3%) were positive, 18,684 (92.1%) were negative, 99 were equivocal (0.5%), and 24 (0.1%) were unsuitable for analysis. Serum EIA testing peaked during the summer months, as did positive results of EIA testing (Supplementary Figure 4) .
During the same period, a total of 1,687 WB tests were performed, including 103 that were positive by EIA at an outside facility and sent for WB testing at UVMMC. Of those, 538 (31.9%) were positive by IgM only, 193 (11.4%) were positive by IgG only, 239 (14.2%) were positive by both, and 716 (42.4%) were negative by both; one was uninterpretable. Positive IgM with negative IgG peaked in the early summer months, which may correspond with early localized disease, while positive IgG results with or without a positive IgM were more sporadic throughout the year (Supplementary Figure 5) . Patients with a positive IgG WB had a bimodal age distribution; median age was 51 years. Males aged 19 years or younger and 50 to 69 years had the highest number of positive IgG WB tests. While more EIA test samples were performed on female patients, more positive IgG WB results were from male patients (Supplementary Figure 6) . Nine synovial fluid samples were sent for PCR testing, and all were negative. Of the 516 CSF samples sent for antibody testing, 14 (2.7%) were positive by EIA (Supplementary Figure 7) . Of these 14 positive EIAs, three CSF samples were negative by WB, seven were positive for IgG but not IgM, and four were positive for both IgG and IgM (Supplementary Figure 7) .
Customer Service Calls
A total of 13 telephone calls related to Lyme disease were logged by laboratory customer service during the study period. Clinicians called with questions regarding testing algorithm (seven calls), result interpretation (two calls), adding on tests to patient specimens (two calls), as well as requests for testing outside the recommended CDC guidelines (two calls, request for WB only and request for WB when EIA was negative).
Discussion
This study demonstrated that most clinicians surveyed in Vermont have basic knowledge of Lyme disease diagnostic testing protocols. In our survey, however, most clinicians struggled with recognizing false-positive IgM results in a patient with longstanding symptoms and interpreting WB results with individually positive bands but an overall negative test. Nearly half of survey respondents also indicated that situations such as these caused confusion in their clinical practices on at least one occasion. These data suggest there is a need for additional clinician education regarding Lyme disease testing. Furthermore, there may be a role for laboratories to modify how they report results to improve accuracy of interpretation by clinicians.
At the time of the survey, the UVMMC laboratory reported both IgM and IgG results (whether positive or negative and which bands, if any, were identified), regardless of the time interval of symptoms. If only IgG is positive, the interpretation states, "Indicative of B. burgdorferi infection at some time in the past." If only IgM is positive, the interpretation states, "Indicative of early B. burgdorferi infection. A new serum specimen should be analyzed in 14-21 days to demonstrate seroconversion of IgG. IgM Western blot is of diagnostic utility only during the first four weeks after the onset of disease. Specimens collected more than 1 month following the onset of disease with positive IgM and negative IgG results more likely represent a false positive." If both IgM and IgG are positive, the interpretation states, "Indicative of active or previous B. burgdorferi infection. IgM Western blot is of diagnostic utility only during the first four weeks after the onset of disease." If both are negative, the interpretation states, "Specific serologic response to B. burgdorferi infection is not detected. This may indicate lack of infection, lack of seroconversion, or low/undetectable antibody levels. If clinically indicated, a new serum specimen should be submitted in 7-14 days." On all results, a comment is included that explains the CDC two-tiered approach and band interpretation criteria.
IgM has high rates of cross-reactivity and false-positive results beyond the initial 30-day symptomatic period, and reporting IgM results for patients with symptoms lasting more than 30 days may lead to some confusion, despite comments added to all results. It is possible that some clinicians only read the "positive" or "negative" results without the accompanying interpretation or that there continues to be confusion despite the included comments. To address this issue, the UVMMC laboratory is currently exploring how best to modify the Lyme disease two-tiered test-ordering mechanism such that they are prompted to state whether or not the patient has had symptoms for more than 30 days. If yes, then only the IgG result would be reported; if no, then both the IgM and IgG results would be reported. This would be consistent with the current CDC-recommended guidelines and could minimize the number of false-positive results reported for patients with symptoms more than 30 days.
Positive IgG results were identified during the summer months, as expected, and the groups with the highest proportion of positive tests were similar to the highest risk groups in CDC surveillance data. These results underscore that these particular age and sex groups are at higher risk and would benefit from targeted prevention efforts. Heightened clinician suspicion could enhance early recognition and treatment.
This study was subject to limitations. Results were based on respondents' willingness to complete the survey and therefore were subject to responder bias. However, the respondent characteristics seemed to be representative of the community and encompass many of the challenges in laboratory test ordering and interpretation typically identified. In addition, only 13 phone calls related to Lyme disease were logged by laboratory customer service during the study period, which is lower than expected. This is
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Conant et al / Lyme Disease TesTing in a HigH-inciDence sTaTe likely because the log sheet for this study was an additional form that customer service personnel needed to have on hand and complete. In a busy customer service call center that receives approximately 8,000 phone calls per month, it is possible that some of the phone calls related to Lyme disease were not recorded. Therefore, it is likely that the actual number of phone calls regarding Lyme disease testing and interpretation is higher than captured in this study.
In conclusion, clinicians would benefit from targeted education regarding Lyme disease testing to improve test-ordering practices and accuracy of test interpretation. Furthermore, clinical laboratories could improve their Lyme disease test ordering and reporting system to tailor reporting of test results based on the patient's duration of symptoms (ie, removing IgM WB results from the laboratory report for patients with longstanding symptoms). Last, education of patients regarding unvalidated Lyme disease tests could reduce alternative test-seeking behavior and decrease the burden of requests to clinicians for these tests.
